• Tiziana Life Sciences dosed the first three participants in a Phase 2a trial of intranasal foralumab in ALS.
• No results have been presented; the study is designed to generate safety data and biomarker signals over a 24-week treatment plan.
• Primary readout targets tolerability, with secondary measures aimed at showing immune modulation with potential relevance to neuroinflammation.
• Trial enrollment targets 44 early-stage ALS patients, using a 3:1 randomization between active drug and placebo.
• Program funding includes support from the ALS Association, positioning the asset for a clearer go/no-go decision on further development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609280700OMX_____CNEWS_EN_GNW9834860_en) on September 28, 2026, and is solely responsible for the information contained therein.